PR Newswire All News ReleasesQwen · 实盘不做把握 8/10不做原因:消息已过时
北京时间·🕒 发布 01:03:00·⟳ 抓取 01:19:55 +16m55s·⚡ 决策 08-27 03:20:12 +2h00m·61.6 天前
Hagens Berman律所宣布对HIMS展开证券调查——系7月29日FTC诉讼的衍生事件,无新增事实
本条信号是原告律所Hagens Berman因2026年7月29日FTC起诉HIMS而发布的常规证券调查招揽广告,不含任何新增监管事实、新诉讼进展或新发现。原事件已近一个月,我方案例库显示7月29-31日已多次处理原FTC诉讼并判定不做。今日股价下跌始于盘前,早于本PR发布时间,与本条信号无因果关系。
📄 原文PR Newswire All News Releases↗ 原文
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- On July 29, 2026, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw t…
不做 Hims & Hers Health(HIMS.US)
本条信号是7月29日FTC诉讼的衍生律所招揽广告,不含新增监管事实或诉讼进展。原事件已近一个月且已充分定价(当日跌14.73%);我方案例库确认7月29-31日已多次处理原事件并判定不做。今日下跌始于盘前,早于本PR发布,与本条信号无因果关系。无新催化、无edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
FTC于7月29日起诉HIMS,当日股价跌14.73%至$25;此后股价反弹至$33+。8月26日,原告律所Hagens Berman发布PR宣布调查,这是FTC诉讼的标准衍生动作(律所招揽广告),不含新增事实。我方案例库确认原事件已于7月底处理。今日-6.46%的跌幅始于盘前,与本PR无时间因果关系。无新催化、无edge、事件已陈旧。
🔎 新鲜度:最早出现 2026-07-29 · 扩散 high · price-in 风险 high ↗
消息传播链
- 2026-07-29 12:00 ET首发FTC/美国联邦法院声称一手 · 未核验FTC联合犹他州和洛杉矶县在加州北区联邦法院正式起诉Hims & Hers,指控欺骗性数据共享和违反ROSCA;HIMS当日跌14.73%至$25.00市场反应:HIMS当日收跌14.73%至$25.00,成交额放大
- 原告律所发布常规调查招揽广告,不含新增监管事实;发布时间晚于当日股价下跌启动(盘前已跌2.24%),非今日下跌的驱动因素
先例如何影响了这次决策
对本次决策的影响:因事件判定为陈旧衍生信号,未进入先例研究阶段
工具调用 · 历史记录,结果未知(5 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- stock_quote · 结果未知
- search_case_library · 结果未知
- web_search · 结果未知
原文全文
展开原文 · 4,248 字
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- On July 29, 2026, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares slide about 14% lower on news that the FTC sued the company over alleged improper business practices.
The events have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Hims & Hers might have engaged in unlawful business practices and, if so, whether such conduct violated the U.S. securities laws.
The firm encourages HIMS investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys.
Visit Hims Investigation Page: www.hbsslaw.com/cases/hims-hers-health-inc-hims-investigation
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895
What Drove the $HIMS Stock Crash? The FTC and State Lawsuit Breakdown
On July 29, 2026, the FTC—alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California)—filed a sweeping federal complaint against Hims & Hers in the U.S. District Court for the Northern District of California (FTC et al. v. Hims & Hers Health, Inc.).
The market reaction was immediate. HIMS shares fell $4.32, or 14.73%, to close at $25.00 per share, as market participants digested the severity of the dual-pronged allegations:
- Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching.
- Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form—long before receiving any consultation with a medical provider—while facing dark patterns and hidden cancellation options designed to prevent subscription termination.
HIMS Stock Investigation: Focus on Financial Reporting & Compliance
While the headline action is a government enforcement proceeding, Hagens Berman is probing deeper. The firm's investigation focuses on whether HIMS management maintained adequate internal controls and whether public filings accurately reflected the regulatory exposure associated with its alleged tracking pixels and billing funnels.
"If the FTC's allegations hold true, we are closely examining what implications these systemic practices carry for the historical accuracy of HIMS' financial reporting and disclosures to the public markets," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SOURCE Hagens Berman Sobol Shapiro LLP
The events have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Hims & Hers might have engaged in unlawful business practices and, if so, whether such conduct violated the U.S. securities laws.
The firm encourages HIMS investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys.
Visit Hims Investigation Page: www.hbsslaw.com/cases/hims-hers-health-inc-hims-investigation
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895
What Drove the $HIMS Stock Crash? The FTC and State Lawsuit Breakdown
On July 29, 2026, the FTC—alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California)—filed a sweeping federal complaint against Hims & Hers in the U.S. District Court for the Northern District of California (FTC et al. v. Hims & Hers Health, Inc.).
The market reaction was immediate. HIMS shares fell $4.32, or 14.73%, to close at $25.00 per share, as market participants digested the severity of the dual-pronged allegations:
- Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching.
- Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form—long before receiving any consultation with a medical provider—while facing dark patterns and hidden cancellation options designed to prevent subscription termination.
HIMS Stock Investigation: Focus on Financial Reporting & Compliance
While the headline action is a government enforcement proceeding, Hagens Berman is probing deeper. The firm's investigation focuses on whether HIMS management maintained adequate internal controls and whether public filings accurately reflected the regulatory exposure associated with its alleged tracking pixels and billing funnels.
"If the FTC's allegations hold true, we are closely examining what implications these systemic practices carry for the historical accuracy of HIMS' financial reporting and disclosures to the public markets," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SOURCE Hagens Berman Sobol Shapiro LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。